CD274 and hepatocellular carcinoma: The HIMALAYA study (NCT03298451), an ongoing open-label, multicenter, randomized phase III trial, is evaluating the efficacy of tremelimumab (anti-CTLA-4 mAb) plus durvalumab (anti-PD-L1 mAb) in the treatment of patients with no prior systemic therapy for unresectable HCC.